Amicus Therapeutics Inc (LTS:0HF9)
$ 9.978 -0.0808 (-0.8%) Market Cap: 2.98 Bil Enterprise Value: 3.18 Bil PE Ratio: 0 PB Ratio: 16.66 GF Score: 81/100

Amicus Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 12, 2022 / 08:45PM GMT
Release Date Price: $10.36 (+8.37%)
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

Welcome, everyone, to the 40th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan, joined by Cable Smith, Malcolm Kuno and Priyanka Grover from the team. Our next presenting company is Amicus Therapeutics. And presenting on behalf of this company, we have CEO, John Crowley, and incoming CEO, Bradley Campbell. (Operator Instructions)

With that, John, Brad, take it away.

John F. Crowley
Amicus Therapeutics, Inc. - Chairman & CEO

Great. I'll go ahead and begin Anupam. Thank you, and thanks, everybody, for joining. This is going to be a very exciting year for Amicus as we're poised to launch our second medicine in the last several years for people living with rare diseases. So we'll come to that on the first slide here, I'll just reference that Bradley, and I will be making forward-looking statements. And then on the next slide, if we fast forward to Slide 4, you'll see a snapshot of Amicus and who we are today.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot